FILING ANALYSIS · TUESDAY, NOVEMBER 3
Beam Therapeutics Inc. BEAM — 8-K: Results of Operations and Financial Condition
neutral
Beam Therapeutics reported third quarter 2026 financial results, highlighting clinical progress across its base editing portfolio, including updated Phase 1/2 clinical data for BEAM-302 and plans to initiate dosing for BEAM-304 in early 2027, with a cash runway expected to support operating plans into mid-2029.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →